Chemical compensation of mitochondrial phospholipid depletion in yeast and animal models of Parkinson's disease

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Wang, Shaoxiao ^a   Zhang, Siyuan ^b   Xu, Chuan ^b   Barron, Addie ^a   Galiano, Floyd ^a   Patel, Dhaval ^a   Lee, Yong Joo ^a   Caldwell, Guy A ^b   Caldwell, Kim A ^b   Witt, Stephan N ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CARDIOLIPIN; CARDIOLIPIN SYNTHASE; CYCLOSPORIN A; MECLOFENOXATE; MESSENGER RNA; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE DECARBOXYLASE; SULFAPHENAZOLE; SYNTHETASE; UNCLASSIFIED DRUG; CAENORHABDITIS ELEGANS PROTEIN; CARBOXYLYASE; CARDIOLIPIN SYNTHETASE; CYCLOSPORIN; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; PHOSPHOTRANSFERASE; PROTECTIVE AGENT; PSD1 PROTEIN, S CEREVISIAE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAENORHABDITIS ELEGANS; CELL STRESS; CELL SURVIVAL; CELL WALL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PROTEIN EXPRESSION; RNA INTERFERENCE; SACCHAROMYCES CEREVISIAE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; SOLUBILITY;

ALPHA-SYNUCLEIN; ANIMALS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CARBOXY-LYASES; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; ENDOPLASMIC RETICULUM STRESS; MECLOFENOXATE; MEMBRANE PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PARKINSON DISEASE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; PROTECTIVE AGENTS; SACCHAROMYCES CEREVISIAE; SOLUBILITY; SULFAPHENAZOLE; TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS);

EID: 84991409051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0164465     Document Type: Article

References (58)

1. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005; 28: 57-87. PMID: 16022590
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M, et al. Alpha-synuclein in Lewy bodies. Nature. 1997; 388(6645):839-840. PMID: 9278044
3. Kara E, Lewis PA, Ling H, Proukakis C, Houlden H, Hardy J. alpha-Synuclein mutations cluster around a putative protein loop. Neurosci Lett. 2013; 546:67-70. doi:10.1016/j.neulet.2013.04.058 PMID: 23669636
4. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. PMID: 14593171
5. Sharon R, Goldberg M, Bar-Josef I, Betensky R, Shen J, Selkoe D. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci. 2001; 98(16):9110-9115. PMID: 11481478
6. Varkey J, Mizuno N, Hegde BG, Cheng N, Steven AC, Langen R. alpha-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. J Biol Chem. 2013; 288(24):17620-17630. doi:10.1074/jbc.M113.476697 PMID: 23609437
7. Eichmann C, Campioni S, Kowal J, Maslennikov I, Gerez J, Liu X, et al. Preparation and characterization of stable α-synuclein lipoprotein particles. J Biol Chem. 2016; 291(16):8516-8527. doi:10.1074/jbc.M115.707968 PMID: 26846854
8. Burre J, Sharma M, Suedhof TC. alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA. 2014; 111(40):E4274-E4283. doi:10.1073/pnas.1416598111 PMID: 25246573
9. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PTJ. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996; 35:13709-13715. PMID: 8901511
10. Chandra S, Chen XC, Rizo J, Jahn R, Sudhof TC. A broken alpha-helix in folded alpha-synuclein. J Biol Chem. 2003; 278(17):15313-15318. PMID: 12586824
11. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001; 40(26):7812-7819. PMID: 11425308
12. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-Synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338 (6109):949-953. doi:10.1126/science.1227157 PMID: 23161999
13. Riekkinen P, Rinne UK, Pelliniemi TT, Sonninen V. Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. Arch Neurol. 1975; 32(1):25-27. PMID: 1115656
14. Manyam BV, Ferraro TN, Hare TA. Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa. Arch Neurol. 1988; 45(1):48-50. PMID: 3337677
15. Ross BM, Mamalias N, Moszczynska A, Rajput AH, Kish SJ. Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease. Neuroscience. 2001; 102 (4):899-904. PMID: 11182251
16. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain. 2009; 132:3285-3297. doi:10.1093/brain/awp293 PMID: 19952056
17. Rappley I, Myers DS, Milne SB, Ivanova PT, LaVoie MJ, Brown HA, et al. Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J Neurochem. 2009; 111(1):15-25. doi:10.1111/j.1471-4159.2009.06290.x PMID: 19627450
18. Vance JE, Tasseva G. Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. Biochim Biophys Acta-Mol Cell Biol Lipids. 2013; 1831(3):543-554.
19. Schuiki I, Daum G. Phosphatidylserine decarboxylases, key enzymes of lipid metabolism. IUBMB Life. 2009; 61(2):151-162. doi:10.1002/iub.159 PMID: 19165886
20. Kainu V, Hermansson M, Hanninen S, Hokynar K, Somerharju P. Import of phosphatidylserine to and export of phosphatidylethanolamine molecular species from mitochondria. Biochim Biophys Acta-Mol Cell Biol Lipids. 2013; 1831(2):429-437.
21. Baker CD, Basu Ball W, Pryce E, N, Gohil VM. Specific requirements of nonbilayer phospholipids in mitochondrial respiratory chain function and formation. Mol Biol Cell. 2016; 27(14):2161-2171. doi:10.1091/mbc.E15-12-0865 PMID: 27226479
22. Gibellini F, Smith TK. The Kennedy Pathway-de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life. 2010; 62(6):414-428. doi:10.1002/iub.337 PMID: 20503434
23. Patil VA, Fox JL, Gohil VM, Winge DR, Greenberg ML. Loss of cardiolipin leads to perturbation of mitochondrial and cellular iron homeostasis. J Biol Chem. 2013; 288(3):1696-1705. doi:10.1074/jbc.M112.428938 PMID: 23192348
24. Wang S, Zhang S, Liou L-C, Ren Q, Zhang Z, Caldwell GA, et al. Phosphatidylethanolamine deficiency disrupts alpha-synuclein homeostasis in yeast and worm models of Parkinson disease. Proc Natl Acad Sci USA. 2014; 111(38):E3976-E3985. doi:10.1073/pnas.1411694111 PMID: 25201965
25. Jung US, Sobering AK, Romeo MJ, Levin DE. Regulation of the yeast Rlm1 transcription factor by the Mpk1 cell wall integrity MAP kinase. Mol Microbiol. 2002; 46(3):781-789. PMID: 12410835
26. Cao SS, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci. 2005; 25(15):3801-3812. PMID: 15829632
27. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci USA. 2008; 105(2):728-733. doi:10.1073/pnas.0711018105 PMID: 18182484
28. Harrington AJ, Yacoubian TA, Slone SR, Caldwell KA, Caldwell GA. Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease. J Neurosci. 2012; 32(6):2142-2153. doi:10.1523/JNEUROSCI.2606-11.2012 PMID: 22323726
29. Holthuis JCM, Menon AK. Lipid landscapes and pipelines in membrane homeostasis. Nature. 2014; 510(7503):48-57. doi:10.1038/nature13474 PMID: 24899304
30. Gohil VM, Thompson MN, Greenberg ML. Synthetic lethal interaction of the mitochondrial phosphatidylethanolamine and cardiolipin biosynthetic pathways in Saccharomyces cerevisiae. J Biol Chem. 2005; 280(42):35410-35416. PMID: 16036913
31. Zs-Nagy I. A survey of the available data on a new nootropic drug, BCE-001. Ann N Y Acad Sci. 1994; 717:102-114. PMID: 8030826
32. Hansson MJ, Persson T, Friberg H, Keep MF, Rees A, Wieloch T, et al. Powerful cyclosporin inhibition of calcium-induced permeability transition in brain mitochondria. Brain Res. 2003; 960(1-2):99-111. PMID: 12505662
33. Hansson MJ, Mansson R, Mattiasson G, Ohlsson J, Karlsson J, Keep MF, et al. Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition. J Neurochem. 2004; 89(3):715-729. PMID: 15086528
34. Nehru B, Verma R, Khanna P, Sharma SK. Behavioral alterations in rotenone model of Parkinson's disease: Attenuation by co-treatment of centrophenoxine. Brain Res. 2008; 1201:122-127. doi:10.1016/j.brainres.2008.01.074 PMID: 18308296
35. Verma R, Nehru B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem Int. 2009; 55(6):369-375. doi:10.1016/j.neuint.2009.04.001 PMID: 19375462
36. Parthasarathy S, Cady RK, Kraushaar DS, Sladek NE, Baumann WJ. Inhibition of diacylglycerol: CDPcholine cholineohophotransferase activity by dimethylaminoethyl p-clorophenoxyacetate. Lipids. 1978; 13(2):161-4. PMID: 204847
37. Parthasarathy S, El-Rahman A, Baumann WJ. Inhibition of diacylglycerol cholinephosphotransferase and lysophosphatidylcholine acyltransferase by centrophenoxine and neophenoxine. Biochim Biophys Acta. 1981; 665:345-351. PMID: 6269646
38. Semsei I, Zs.-Nagy I. Superoxide radical scavenging ability of centrophenoxine and its salt dependence in vitro. Free Rad Biol Med. 1985; 1:403-408.
39. Gabriela Malanga MBA, Hugo D. Martinez and Susana Puntarulo. New Insights on Dimethylaminoethanol (DMAE) Features as a Free Radical Scavenger. Drug Metab Lett. 2012; 6:54-59. PMID: 22300295
40. Liu J, Farmer JJ, Lane W, Friedman J, Weissman I, Schreiber S, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66(4):807-815. PMID: 1715244
41. Halestrap A, Davidson A. Inhibition of Ca2(+)-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidylprolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J. 1990; 268(1):153-160. PMID: 2160810
42. Penzo D, Petronilli V, Angelin A, Cusan C, Colonna R, Scorrano L, et al. Arachidonic acid released by phospholipase A(2) activation triggers Ca2+-dependent apoptosis through the mitochondrial pathway. J Biol Chem. 2004; 279(24):25219-25225. PMID: 15070903
43. Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology. 1997; 25(4):958-963. PMID: 9096604
44. Halestrap AP, Richardson AP. The mitochondrial permeability transition: A current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015; 78:129-141. doi:10.1016/j.yjmcc.2014.08.018 PMID: 25179911
45. Martin LJ, Semenkow S, Hanaford A, Wong M. The mitochondrial permeability transition pore regulates Parkinson's disease development in mutant alpha-synuclein transgenic mice. Neurobiol Aging. 2014; 35(5):1132-1152. doi:10.1016/j.neurobiolaging.2013.11.008 PMID: 24325796
46. Warne J, Pryce G, Hill JM, Shi X, Lenneras F, Puentes F, et al. Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in xxperimental multiple sclerosis. J Biol Chem. 2016; 291(9):4356-4373. doi:10.1074/jbc.M115.700385 PMID: 26679998
47. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol. 2005; 351(5):1081-1100. PMID: 16051265
48. Smith WW, Jiang HB, Pei Z, Tanaka Y, Morita H, Sawa A, et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet. 2005; 14(24):3801-3811. PMID: 16239241
49. Bir A, Sen O, Anand S, Khemka VK, Banerjee P, Cappai R, et al. alpha-synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: Implications in the pathogenesis of Parkinson's disease. J Neurochem. 2014; 131(6):868-877. doi:10.1111/jnc.12966 PMID: 25319443
50. Petrosillo G, Ruggiero FM, Pistolese M, Paradies G. Ca2+-induced reactive oxygen species production promotes cytochrome c release from rat liver mitochondria via mitochondrial permeability transition (MPT)-dependent and MPT-independent mechanisms - Role of cardiolipin. J Biol Chem. 2004; 279(51):53103-53108. PMID: 15475362
51. Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang CQ, Sayen MR, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA. 2004; 101(5):1321-1326. PMID: 14734800
52. Booth Depaz IM, Toselli F, Wilce PA, Gillam EM. Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain. Drug Metab Dispos. 2015; 43(3):353-357. doi:10.1124/dmd.114.061242 PMID: 25504503
53. Chang Q, Berdyshev E, Cao D, Bogaard JD, White JJ, Chen S, et al. Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. J Biol Chem. 2014; 289 (12):8337-8352. doi:10.1074/jbc.M113.507152 PMID: 24519941
54. Darios F, Ruiperez V, Lopez I, Villanueva J, Gutierrez LM, Davletov B. alpha-Synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep. 2010; 11(7):528-533. doi:10.1038/embor.2010.66 PMID: 20489724
55. Burke D, Dawson D, Stearns T. Methods in Yeast Genetics. Cold Spring Harbor, NY: Cold Spring Harbor Lab Press; 2000. pp. 103-174.
56. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999; 4(2):67-73. PMID: 10838414
57. Berkowitz LA, Hamamichi S, Knight AL, Harrington AJ, Caldwell GA, Caldwell KA. Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes. J Vis Exp. 2008;(17: ):835. doi:10.3791/835 PMID: 19066512
58. Ray A, Zhang SG, Rentas C, Caldwell KA, Caldwell GA. RTCB-1 mediates neuroprotection via XBP-1 mRNA slpicing in the unfolded protein response pathway. J Neurosci. 2014; 34(48):16076-16085. doi:10.1523/JNEUROSCI.1945-14.2014 PMID: 25429148